ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
Revelation Biosciences Inc

Revelation Biosciences Inc (REVB)

0.4698
-0.0352
(-6.97%)
終了 12月5日 6:00AM
0.49
0.0202
( 4.30% )
プレマーケット: 10:09PM

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

主要統計と詳細

通貨
0.49
買値
0.49
売値
0.50
出来高
392,903
0.00 日の範囲 0.00
0.2924 52 週間の範囲 25.26
時価総額
前日終値
0.4698
始値
-
最終取引時間
22:09:18
財務取引量
-
VWAP
-
平均取引量 (3 か月)
951,097
発行済株式数
4,292,455
配当利回り
-
PER
-0.36
1 株当たり利益 (EPS)
-0.03
歳入
-
純利益
-120k

Revelation Biosciences Inc について

Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to ... Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99. 詳細を表示

セクター
Pharmaceutical Preparations
業界
Blank Checks
本社
Lewes, Delaware, USA
設立
2022
Revelation Biosciences Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker REVB. The last closing price for Revelation Biosciences was US$0.47. Over the last year, Revelation Biosciences shares have traded in a share price range of US$ 0.2924 to US$ 25.26.

Revelation Biosciences currently has 4,292,455 shares in issue. The market capitalisation of Revelation Biosciences is US$2.02 million. Revelation Biosciences has a price to earnings ratio (PE ratio) of -0.36.

REVB 最新ニュース

Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds

Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment...

Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND

-Phase 1b Study in CKD Patients to begin early 2025- Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on...

Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply

Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and...

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024

Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and...

Revelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10

Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention...

Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of...

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024

Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and...

期間 †前日比前日比 %始値高値安値平均出来高VWAP
1-0.27-35.52631578950.760.9760.292460533500.72754759CS
4-0.379901-43.67175115330.8699011.050.292426747630.86616581CS
12-0.41401-45.7970597670.904011.050.29249510970.86270341CS
26-1.43-74.47916666671.923.80.292415186101.73317821CS
52-20.51-97.66666666672125.260.29249009952.57840585CS
156-8798.51-99.9944311854879910237.50.29241275987778.49911094CS
260-8798.51-99.9944311854879910237.50.29241275987778.49911094CS

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
PRFXPainReform Ltd
US$ 6.38
(138.06%)
15.36M
RKDAArcadia Biosciences Inc
US$ 5.16
(91.32%)
740.16k
BJDXBluejay Diagnostics Inc
US$ 7.14
(83.55%)
11.19M
SVMHSRIVARU Holding Ltd
US$ 0.0346
(47.23%)
250.48M
PBMPsyence Biomedical Ltd
US$ 3.59
(42.46%)
13.46M
BLUEbluebird bio Inc
US$ 0.5178
(-29.68%)
1.6M
CYCNCyclerion Therapeutics Inc
US$ 4.65
(-26.77%)
304.49k
STECSantech Holdings Limited
US$ 0.745
(-23.20%)
3.93M
SRMSRM Entertainment Inc
US$ 0.915
(-21.12%)
1.11M
NCNOnCino Inc
US$ 33.94
(-20.14%)
99.98k
SVMHSRIVARU Holding Ltd
US$ 0.0346
(47.23%)
250.48M
TARAProtara Therapeutics Inc
US$ 4.92
(38.98%)
16.03M
PRFXPainReform Ltd
US$ 6.38
(138.06%)
15.36M
PBMPsyence Biomedical Ltd
US$ 3.59
(42.46%)
13.46M
BJDXBluejay Diagnostics Inc
US$ 7.14
(83.55%)
11.19M

REVB Discussion

投稿を表示

最近閲覧した銘柄

Delayed Upgrade Clock